By Robb M. Stewart
Merck & Co. stated Monday it has utilized to U.S. and European regulators to license V114, its investigational 15-valent pneumococcal conjugate vaccine to be used in adults.
The corporate stated it’s awaiting acceptance of purposes submitted to the U.S. Meals and Drug Administration and the European Medicines Company.
The purposes embody outcomes from Section 2 and Section three scientific research in a wide range of grownup populations, together with wholesome adults and people at elevated threat, equivalent to adults with persistent medical situations, adults with HIV, and people 65 years of age and older, Merck stated.
V114 beforehand acquired breakthrough remedy designation from the FDA for the prevention of invasive pneumococcal illness in pediatric sufferers 6 weeks to 18 years of age and adults 18 years of age and older.
Write to Robb M. Stewart at [email protected]
(END) Dow Jones Newswires